vs
Side-by-side financial comparison of Agilent Technologies (A) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $950.5M, roughly 1.9× Astrana Health, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 0.7%, a 16.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 7.0%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 6.9%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
A vs ASTH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $950.5M |
| Net Profit | $305.0M | $6.6M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | 1.9% |
| Net Margin | 17.0% | 0.7% |
| Revenue YoY | 7.0% | 42.9% |
| Net Profit YoY | -4.1% | 184.4% |
| EPS (diluted) | $1.07 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $950.5M | ||
| Q3 25 | $1.7B | $956.0M | ||
| Q2 25 | $1.7B | $654.8M | ||
| Q1 25 | $1.7B | $620.4M | ||
| Q4 24 | $1.7B | $665.2M | ||
| Q3 24 | $1.6B | $478.7M | ||
| Q2 24 | $1.6B | $486.3M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $6.6M | ||
| Q3 25 | $336.0M | $373.0K | ||
| Q2 25 | $215.0M | $9.4M | ||
| Q1 25 | $318.0M | $6.7M | ||
| Q4 24 | $351.0M | $-7.8M | ||
| Q3 24 | $282.0M | $16.1M | ||
| Q2 24 | $308.0M | $19.2M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 1.9% | ||
| Q3 25 | 20.7% | 2.0% | ||
| Q2 25 | 18.0% | 3.1% | ||
| Q1 25 | 22.4% | 3.3% | ||
| Q4 24 | 24.0% | 0.1% | ||
| Q3 24 | 21.1% | 5.9% | ||
| Q2 24 | 23.1% | 6.2% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 0.7% | ||
| Q3 25 | 19.3% | 0.0% | ||
| Q2 25 | 12.9% | 1.4% | ||
| Q1 25 | 18.9% | 1.1% | ||
| Q4 24 | 20.6% | -1.2% | ||
| Q3 24 | 17.9% | 3.4% | ||
| Q2 24 | 19.6% | 3.9% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.12 | ||
| Q3 25 | $1.18 | $0.01 | ||
| Q2 25 | $0.75 | $0.19 | ||
| Q1 25 | $1.11 | $0.14 | ||
| Q4 24 | $1.23 | $-0.14 | ||
| Q3 24 | $0.97 | $0.33 | ||
| Q2 24 | $1.05 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $429.5M |
| Total DebtLower is stronger | $3.0B | — |
| Stockholders' EquityBook value | $6.9B | $779.3M |
| Total Assets | $12.8B | $2.2B |
| Debt / EquityLower = less leverage | 0.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $429.5M | ||
| Q3 25 | $1.5B | $463.4M | ||
| Q2 25 | $1.5B | $342.1M | ||
| Q1 25 | $1.5B | $260.9M | ||
| Q4 24 | $1.3B | $290.8M | ||
| Q3 24 | $1.8B | $350.3M | ||
| Q2 24 | $1.7B | $327.7M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $779.3M | ||
| Q3 25 | $6.4B | $775.5M | ||
| Q2 25 | $6.1B | $765.5M | ||
| Q1 25 | $6.0B | $745.4M | ||
| Q4 24 | $5.9B | $712.7M | ||
| Q3 24 | $5.9B | $704.6M | ||
| Q2 24 | $6.2B | $678.9M |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $2.2B | ||
| Q3 25 | $12.2B | $2.2B | ||
| Q2 25 | $12.2B | $1.4B | ||
| Q1 25 | $11.9B | $1.3B | ||
| Q4 24 | $11.8B | $1.4B | ||
| Q3 24 | $11.0B | $1.3B | ||
| Q2 24 | $10.9B | $1.3B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $-2.9M |
| Free Cash FlowOCF − Capex | $175.0M | $-6.0M |
| FCF MarginFCF / Revenue | 9.7% | -0.6% |
| Capex IntensityCapex / Revenue | 5.2% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.88× | -0.44× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $104.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-2.9M | ||
| Q3 25 | $362.0M | $10.0M | ||
| Q2 25 | $221.0M | $90.9M | ||
| Q1 25 | $431.0M | $16.6M | ||
| Q4 24 | $481.0M | $-10.9M | ||
| Q3 24 | $452.0M | $34.0M | ||
| Q2 24 | $333.0M | $23.2M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-6.0M | ||
| Q3 25 | $259.0M | $7.4M | ||
| Q2 25 | $107.0M | $89.5M | ||
| Q1 25 | $334.0M | $13.6M | ||
| Q4 24 | $388.0M | $-13.5M | ||
| Q3 24 | $360.0M | $31.7M | ||
| Q2 24 | $230.0M | $20.4M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -0.6% | ||
| Q3 25 | 14.9% | 0.8% | ||
| Q2 25 | 6.4% | 13.7% | ||
| Q1 25 | 19.9% | 2.2% | ||
| Q4 24 | 22.8% | -2.0% | ||
| Q3 24 | 22.8% | 6.6% | ||
| Q2 24 | 14.6% | 4.2% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 0.3% | ||
| Q3 25 | 5.9% | 0.3% | ||
| Q2 25 | 6.8% | 0.2% | ||
| Q1 25 | 5.8% | 0.5% | ||
| Q4 24 | 5.5% | 0.4% | ||
| Q3 24 | 5.8% | 0.5% | ||
| Q2 24 | 6.5% | 0.6% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | -0.44× | ||
| Q3 25 | 1.08× | 26.69× | ||
| Q2 25 | 1.03× | 9.65× | ||
| Q1 25 | 1.36× | 2.48× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | 2.11× | ||
| Q2 24 | 1.08× | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
